Stevanato Group (STVN)

Executive Summary

Stevanato Group is a leading global provider of integrated drug containment, delivery, and diagnostic solutions, serving pharmaceutical and biotech customers from development through commercialization. With a 75-year history, the company offers high-quality glass vial systems, advanced drug delivery devices like autoinjectors, and manufacturing services. Stevanato is well-positioned to benefit from the growing demand for GLP-1 receptor agonist drugs, which require specialized containment and delivery solutions. Recent investments in capacity expansion and strategic partnerships support its growth trajectory. However, the company faces cyclical pharma spending and competition in the drug delivery market. Overall, Stevanato's strong market position, end-to-end portfolio, and exposure to high-growth therapeutic areas underpin our conviction.

Upcoming Catalysts (preview)

• Q3 2026Major auto-injector manufacturing contract wins for GLP-1 drugs80% success
• Q2 2027Completion of new glass vial capacity expansion to meet tightening supply70% success
• TBDPotential strategic acquisition to enhance drug delivery technology portfolio50% success